Merus Labs International Inc. Form 6-K August 28, 2014

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 6-K

### **REPORT OF FOREIGN PRIVATE ISSUER**

### PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2014

Commission File No. 00-30082

## **MERUS LABS INTERNATIONAL INC.**

(Translation of registrant's name into English)

### 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F **Form 20-F [X]** Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ]

### SUBMITTED HEREWITH

Exhibits	
<u>99.1</u>	News Release dated August 14, 2014
<u>99.2</u>	Material Change Report dated August 28, 2014

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 28, 2014

### MERUS LABS INTERNATIONAL INC.

<u>/s/ Andrew Patient</u> Andrew Patient Chief Financial Officer